The United Kingdom and the United States have signed a major trade agreement that will guarantee zero import taxes on UK drug products entering the US market.
Agreement Details of the Deal
In exchange for the tariff guarantee, the UK has agreed to raise funding on pharmaceuticals through the NHS. This move guarantees that import taxes on these vital products will stay at nothing for a period of 36 months.
This agreement is in response to previous warnings to significantly raise tariffs on patented pharmaceutical imports, with increases discussed as high as 100%.
"This agreement between the UK bolsters the international landscape for innovative medicines and brings long-overdue equity to American-British medicine commerce," an announcement said.
Economic Importance
Drugs are one of the UK's largest export categories to the America, which is by far the largest destination for major UK drugmakers.
Statistics show that in the 12 months leading up to the third quarter, the UK exported pharmaceutical products worth billions to the US. This figure made up 17.4% of British export trade in that period.
"This agreement protects work, stimulates capital expenditure and facilitates the UK to emerge as a international leader for biotech and pharma," a government official remarked.
Detailed NHS Changes
The agreement includes several key commitments from the United Kingdom:
- Higher Cost Ceiling: The UK will increase the price threshold at which it considers new medicines to be prohibitively costly by twenty-five percent.
- Boosted Medicine Funding: There is a aim to increase total public funding on treatments from 0.3% of Gross Domestic Product to 0.6% over the next decade.
- Payback Limit: The percentage drug companies must refund to the NHS to prevent overspending will be limited at fifteen percent. Previously, rebates exceeded twenty percent.
Recent Tensions
The deal follows a protracted dispute between the drug companies and the UK government over spending levels and approval rates.
The disagreement were heightened by assertions that US consumers were paying several times more for the same drugs than consumers in the other developed nations.
Recently, several significant drug company projects in the UK have been delayed or cancelled, while major expansions have been directed toward US facilities.
One official acknowledged that the NHS must invest a greater share on treatments, noting that its expenditure on drugs had shrunk as a share of its total funding over the past decade.
